How Vu Technologies CEO Ido Wiesenberg grew Vu Technologies to $29.6M revenue with a 163 person team in 2025.

Elucidata Corporation

Provider of cloud-based data analytics platform designed to analyze omics datasets to understand the molecular basis of cellular phenotypes. The company's platform can process, analyze and visualize large omics data across metabolic, genomics, transcriptomics and proteomics among others and uses data analytics to transform decision making processes in research and development labs in biotechnology and pharmaceutical businesses, enabling scientists and doctors in biotech, pharma and hospitals to make real-time decisions.

Teamwork Commerce

Provider of software services for the retail market. The company offers mobile, cloud-based retail management application that delivers omni channel experience, while providing effortless implementations and a simple-to-use interface simplifying the retail sector and improving the customer's shopping experience.

SuperU AI

White-label AI voice calls to scale campaigns—no code needed.

Agendia

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/

Deepen AI

Founded in 2017, Deepen AI is the only safety-first data lifecycle tools and services company focused on unlocking the potential of machine learning and AI for autonomous systems. Our tools and services are customizable to suit the needs of enterprises as well as start-ups.

Skan AI

Skan AI is the enterprise system of record for work intelligence, powering AI agents trained on operational reality, not documentation, system logs, or assumptions. We capture how work actually happens across your entire application stack, translating human intelligence and intent into the ground truth data AI agents need to handle your unique enterprise complexity autonomously.